These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 23564814)
21. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549 [TBL] [Abstract][Full Text] [Related]
22. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. Lin CK; Chao TK; Lai HC; Lee HS Am J Clin Pathol; 2012 Jun; 137(6):971-7. PubMed ID: 22586057 [TBL] [Abstract][Full Text] [Related]
23. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453 [TBL] [Abstract][Full Text] [Related]
24. Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma. Orsaria M; Londero AP; Marzinotto S; Di Loreto C; Marchesoni D; Mariuzzi L Cancer Biomark; 2016; 17(4):479-486. PubMed ID: 27802199 [TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678 [TBL] [Abstract][Full Text] [Related]
26. Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. Turunen M; Talvensaari-Mattila A; Soini Y; Santala M Anticancer Res; 2009 Dec; 29(12):5185-9. PubMed ID: 20044634 [TBL] [Abstract][Full Text] [Related]
27. [Clinical and pathological features of borderline ovarian tumors]. Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693 [TBL] [Abstract][Full Text] [Related]
28. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324 [TBL] [Abstract][Full Text] [Related]
30. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. Karaferic A; Jovanovic D; Jelic S J BUON; 2009; 14(4):635-9. PubMed ID: 20148455 [TBL] [Abstract][Full Text] [Related]
31. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer]. Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700 [TBL] [Abstract][Full Text] [Related]
32. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma]. Zhang MZ; Qiao YH; Suo ZH Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831 [TBL] [Abstract][Full Text] [Related]
34. Clinical factors and biomarkers in ovarian tumors development. Vrabie CD; Petrescu A; Waller M; Dina I Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637 [TBL] [Abstract][Full Text] [Related]
35. [Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors]. Zhang CY; Guo HY; Li H; Wen HW; Liang XD; Qiao J Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):688-91. PubMed ID: 23159083 [TBL] [Abstract][Full Text] [Related]
36. Analysis of potential prognostic factors in 111 patients with ovarian cancer. Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165 [TBL] [Abstract][Full Text] [Related]
37. Clinicopathological significance of DEK overexpression in serous ovarian tumors. Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407 [TBL] [Abstract][Full Text] [Related]
38. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Ayhan A; Guven S; Guven ES; Kucukali T Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366 [TBL] [Abstract][Full Text] [Related]
40. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]